Ras Effector RASSF10 locks the metabolic reprogramming mechanism in tumour cells
Implementing Organization
Principal Investigator
Prof. Sundarasamy Mahalingam
Indian Institute of Technology(IIT) Madras
About
Tumour development is a multistep process with different biological capabilities acquired at each stage. Deregulation in developmental pathways, including RAS, alters cell fate decisions. RASSF10, a member of novel nonenzymatic RAS effectors, is downregulated in 60% of cancers through hypermethylation. It inhibits cell proliferation, survival, and migration. RASSF10 downregulates GNL3L and IMPDH2 expression, which are overexpressed in many solid tumors and negatively correlate with patient survival. Understanding RASSF10's function is crucial for cancer treatment.
Science and Engineering Research Board (SERB), New Delhi
Quick Information
Area of Research
Life Sciences & Biotechnology
Focus Area
Biotechnology
Start Year
2023
End Year
2025
Sanction Amount
₹ 76.10 L
Status
Completed
Contact
sundarmahalingam1964@gmail.com
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
00
No. of Patents
Filed :00
Grant :00
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.
Indian Institute of Technology(IIT) Madras
Acces sibility Controls